MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us





Back to products


 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries


Other drug agents

Drug intermediates

Bio-reagents and biochemicals









MedKoo product information:




Description of  Cerovive:   Cerovive, also known as OKN007, NXY-059,  is a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), with potential anti-glioma activity. Although the exact mechanism(s) of action of OKN007 are still largely unknown, this agent appears to inhibit cancer cell proliferation and migration. This agent appears to inhibit the activity of sulfatase 2 (SULF2), a highly specific endoglucosamine-6-sulfatase that is overexpressed in the extracellular matrix of cancer cells and catalyzes the removal of sulfate from the 6-O-sulfate esters of heparin. In addition, OKN007 may induce changes in tumor metabolism and scavenge free radicals. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)


Current developer: Oklahoma Medical Research Foundation.


MedKoo Cat#: 205890

Name:  Cerovive

CAS#:  168021-79-2

Synonym: OKN-007, OKN007; OKN 007. 2,4-disulfonyl PNB, NXY-059, Cerovive

IUPAC/Chemical name: 

sodium (Z)-4-((tert-butyloxidoimino)methyl)benzene-1,3-disulfonate  

Chemical structure

Theoretical analysis

MedKoo Cat#: 205890
Name: Cerovive
CAS#:  168021-79-2

Chemical Formula: C11H13NNa2O7S2
Exact Mass: 380.99288
Molecular Weight: 381.33
Elemental Analysis: C, 34.65; H, 3.44; N, 3.67; Na, 12.06; O, 29.37; S, 16.82


Availability and price:


This agent is available through  custom synthesis.



Technical data

Product data sheet

View product data sheet


white solid powder


>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

View current batch of CoA

QC data:

View NMR, View HPLC, View MS

Safety Data Sheet (MSDS):

View Material Safety Data Sheet (MSDS)

Shipping condition:

Shipped under ambient temperature as non-hazardous chemical.  This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).


Soluble in DMSO, not in water

Shelf life:

>2 years if stored properly

Drug formulation:

This drug may be formulated in DMSO

Stock solution storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Note: The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

 Protocols from literature

In vitro protocol::


In vivo protocol:


Clinical study:


Review papers:




Highlights of recent research using this agent

OKN-007 is a proprietary compound that has had extensive commercial development (designated as NXY-059) for another indication, acute ischemic stroke, and after extensive clinical studies was shown to lack efficacy for this indication but was shown to be very safe for human use. This compound administered orally in the rat glioma model has potent activity in treating fully formed gliomas.  ( 2011 May 1;11(4):373-9.).  




1: Floyd RA, Castro Faria Neto HC, Zimmerman GA, Hensley K, Towner RA. Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. Free Radic Biol Med. 2013 Sep;62:145-56. doi: 10.1016/j.freeradbiomed.2013.01.033. Epub 2013 Feb 16. Review. PubMed PMID: 23419732; PubMed Central PMCID: PMC3715559.

2: Towner RA, Gillespie DL, Schwager A, Saunders DG, Smith N, Njoku CE, Krysiak RS 3rd, Larabee C, Iqbal H, Floyd RA, Bourne DW, Abdullah O, Hsu EW, Jensen RL. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncol. 2013 Mar;15(3):330-40. doi: 10.1093/neuonc/nos337. Epub 2013 Jan 17. PubMed PMID: 23328810; PubMed Central PMCID: PMC3578492.

3: Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, Floyd RA, Roberts LR. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. doi: 10.1002/gcc.22022. Epub 2012 Oct 29. PubMed PMID: 23109092; PubMed Central PMCID: PMC3889201.

4: Floyd RA, Chandru HK, He T, Towner R. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem. 2011 May 1;11(4):373-9. Review. PubMed PMID: 21651461; PubMed Central PMCID: PMC3246679.

5: Garteiser P, Doblas S, Watanabe Y, Saunders D, Hoyle J, Lerner M, He T, Floyd RA, Towner RA. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Reson Imaging. 2010 Apr;31(4):796-806. doi: 10.1002/jmri.22106. PubMed PMID: 20373422.




Contact MedKoo:

Tel: 919-636-5577
Fax: 919-980-4831


(Keyword; CAS#; MedKoo Cat#)








About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved